

### Market Snapshot (Updated at 8AM)

Indian Indices	Close	Net Chng.	Chng. (%)
Sensex	62681.84	177.04	0.28
Nifty	18618.05	55.30	0.30

Global Indices	Close	Net Chng.	Chng. (%)
DOW JONES	33852.53	3.07	0.01
NASDAQ COM.	10983.78	65.72	0.59
FTSE 100	7512.00	37.98	0.51
CAC 40	6668.97	3.77	0.06
DAX	14355.45	27.91	0.19
NIKKEI 225	27847.80	180.82	0.65
SHANGHAI	3151.54	0.75	0.02
HANG SENG	18215.33	0.18	0.00

Currency	Close	Net Chng.	Chng. (%)
USD / INR	81.73	0.06	0.07
USD / EUR	1.03	0.00	0.05
USD / GBP	1.20	0.00	0.05
USD / JPY	138.64	0.18	0.13

Precious Metals	Close	Net Chng.	Chng. (%)
Gold (USD)	1752.05	2.29	0.13
Silver	21.42	0.01	0.05

Energy	Close	Net Chng.	Chng. (%)
NYMEX Crude	78.92	0.75	0.96
Brent Crude	83.88	0.85	1.02
Natural Gas	7.12	0.12	1.62

Bond	Close	Net Chng.	Chng. (%)
10 Yrs G-Sec	7.28	0.01	0.08

Indian ADRs	Close	Net Chng.	Chng. (%)
Dr. Reddy's Lab	55.29	0.73	1.34
HDFC Bank	69.24	0.65	0.95
ICICI Bank	23.48	0.31	1.34
Infosys Ltd	19.71	0.08	0.41
Tata Motors	26.39	0.13	0.50
Wipro	4.95	0.00	0.00

### Institutional Flow (In Crore) 29-11-2022

Institution	Purchase	Sale	Net
FII	6600.32	5358.75	1241.57
DII	5682.24	6426.66	744.42

### Key Contents

- ⇒ [Market Outlook/Recommendation](#)
- ⇒ [Today's Highlights](#)
- ⇒ [Global News, Views and Updates](#)
- ⇒ [Links to important News highlight](#)

### Top News for Today

- **New Delhi Television:** Founders Prannoy Roy and Radhika Roy resigned from the board of the company's promoter group RRPR Holding.
- **Gland Pharma:** The company entered into a put option agreement to acquire 100% stake in France-based Phixen SAS, doing business under the brand name Cenexi, for 210 million euros (Rs 1,775.37 crore).
- **Biocon:** The company's subsidiary Biocon Biologics completed the acquisition of the biosimilars businesses and assets of Viatriis.
- **SBI/ HDFC Bank/ICICI Bank/Yes Bank/IDFC First Bank/Bank of Baroda/Union Bank of India/Kotak Mahindra Bank:** The Reserve Bank of India will start the pilot of for retail digital rupee on Dec. 01 through these eight banks.
- **IDFC:** SEBI has approved handing over control of IDFC Mutual Fund to a consortium led by Bandhan Financial Holdings.
- **Inox Wind/Inox Green Energy Services:** The companies have started the process of deleveraging their balance sheets, reducing a total debt of Rs 411 crore.
- **Krishna Institute of Medical Sciences:** The company raised its shareholding in subsidiary Arunodaya Hospitals to 65.62% by acquiring additional 7.79% stake.

### Events of the Day

- **Gujarat Themis Biosyn:** To meet investors and analysts on Nov. 30.
- **UNO Minda:** To meet investors and analysts on Nov. 30.
- **Clean Science and Technology:** To meet investors and analysts on Nov. 30 and Dec. 2.
- **Kalyan Jewellers India:** To meet investors and analysts on Nov. 30.
- **Aether Industries:** To meet investors and analysts on Dec. 1.
- **PI Industries:** To meet investors and analysts on Nov. 30, Dec. 2 and Dec. 6.
- **Deep Industries:** To meet investors and analysts on Nov. 30.
- **Paras Defence and Space Technologies:** To meet investors and analysts on Nov. 30.
- **Themis Medicare:** To meet investors and analysts on Dec. 1.
- **Dhampur Bio Organics:** To meet investors and analysts on Nov. 30.
- **Indiabulls Housing Finance:** To meet investors and analysts on Nov. 30.
- **Apollo Hospitals Enterprise** to consider issue of NCDs on private placement
- **KPI Green Energy** board to consider free shares issue plan

## Market in Detailed (Updated at 8AM)

Indian Indices	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	62681.84	177.04	0.28	2.06	3.19	5.28	9.84
Nifty	18618.05	55.30	0.30	2.05	3.36	4.84	9.63
BSE M Cap	25679.73	99.97	0.39	1.83	1.26	1.07	4.02
BSE S Cap	29341.21	85.53	0.29	2.15	1.82	2.41	5.03
Nifty MC 100	31677.30	141.60	0.45	1.95	0.78	0.62	6.84
BSE Auto	29855.79	75.50	0.25	2.10	2.81	1.58	24.46
BSE Capgoods	33636.90	249.49	0.74	0.39	1.11	4.38	25.08
BSE FMCG	16385.04	279.11	1.73	2.63	1.57	2.70	19.69
BSE Metal	19868.94	113.00	0.57	0.40	4.44	3.67	9.06
BSE Oil&Gas	20440.00	0.02	0.00	4.16	4.89	0.74	16.78
BSE Healthcare	23852.14	127.97	0.54	2.04	0.30	3.64	6.47
BSE Power	4590.90	6.88	0.15	0.24	5.67	12.19	32.82
BSE Realty	3532.31	14.69	0.41	1.29	1.13	4.29	7.04
BSE ConsDur	41216.35	239.30	0.58	0.33	3.41	3.50	4.37
BSE Bank	49117.39	57.18	0.12	1.27	3.63	8.44	20.45
BSE IT	30440.05	38.52	0.13	2.84	5.22	5.27	11.47

LME	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1752.05	2.29	0.13	0.14	7.26	2.40	1.26
Silver(\$/Ounce)	21.27	0.02	0.08	1.22	11.01	18.25	6.83
Aluminium	2344.99	17.23	0.74	2.54	6.55	6.30	11.16
Copper	8036.00	100.75	1.27	0.76	5.47	1.86	16.83
Zinc	2949.50	2.00	0.07	1.50	3.28	19.11	10.69
Lead	2123.00	19.50	0.93	2.21	5.96	7.03	8.04

Currency	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	81.73	0.06	0.07	0.06	1.30	2.15	8.12
USD Index	106.69	0.12	0.11	0.48	4.32	1.84	11.16
YUAN	7.15	0.01	0.10	0.11	2.14	3.66	11.02
GBP	1.20	0.00	0.21	0.65	4.43	3.05	9.94
EUR	1.03	0.00	0.15	0.50	4.69	2.89	8.76
YEN	138.64	0.02	0.01	0.69	7.26	0.22	18.38

Agro Commodities	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	168.90	6.05	3.72	5.30	0.69	26.71	26.99
Cotton	80.32	0.29	0.36	2.55	12.12	27.07	4.16
Sugar	19.53	0.15	0.77	1.66	11.09	6.84	7.78
Wheat	785.00	3.50	0.45	3.15	12.71	7.40	0.92
Soybean	1461.00	1.50	0.10	2.19	2.92	2.33	20.72

Global Indices	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	33852.53	3.07	0.01	0.45	3.42	7.43	1.83
Nasdaq	10983.78	65.72	0.59	0.37	0.04	7.04	29.31
S&P 500	3957.63	6.31	0.16	0.19	2.21	0.07	13.34
FTSE100	7512.00	37.98	0.51	0.79	5.88	3.13	6.41
CAC40	6668.97	3.77	0.06	0.17	6.42	8.88	0.78
DAX	14355.45	27.91	0.19	0.46	8.31	11.85	4.93
Mexico IPC	50174.06	907.27	1.78	3.07	0.50	11.70	0.96
Brazil Bovespa	110909.6	2127.46	1.96	1.72	4.42	1.27	8.83
Russian RTS	1128.71	6.25	0.56	1.21	1.53	10.31	31.42
Japan Nikkei	27847.80	180.82	0.65	0.96	0.94	0.87	0.09
Hang Seng	18215.33	0.18	0.00	3.89	23.95	8.77	22.45
Taiwan Index	14732.37	23.59	0.16	0.85	13.77	2.40	15.46
Shanghai Comp	3151.54	0.75	0.02	1.73	8.88	1.61	11.60
KOSPI	2445.04	10.11	0.42	1.05	6.54	1.15	13.93
Malaysia KLCI	1472.83	4.35	0.29	2.17	0.84	2.61	2.73
Jakarta Comp	7042.22	30.02	0.43	0.17	0.80	1.90	7.78
Philippine SE	6780.78	99.31	1.49	5.46	10.20	2.99	5.83
Thai Exch	1624.39	7.48	0.46	0.56	0.97	0.89	3.55

Freight	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	1327.00	20.00	1.48	15.49	9.30	37.51	56.03
Baltic Dirty	2433.00	35.00	1.42	2.52	33.17	60.91	237.45
SG Dubai HY	25.48	2.40	10.40	18.79	23.39	24.23	638.55

Energy Markets	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	78.92	0.75	0.96	2.47	8.76	11.84	19.30
BRENT Crude	83.88	0.85	1.02	1.79	9.62	9.74	27.67
Natural Gas	7.12	0.12	1.62	3.89	7.73	24.24	62.29

Bond Markets	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	3.74	0.01	0.15	1.24	6.82	20.50	158.85
UK	3.10	0.03	0.83	1.18	10.87	19.14	260.05
Brazil	5.99	0.12	1.95	3.15	5.79	1.75	23.03
Japan	0.25	0.00	0.40	2.01	2.42	11.40	345.61
Australia	3.59	0.02	0.53	0.11	4.02	0.53	112.13
India	7.28	0.01	0.08	0.30	1.87	0.39	14.90
Switzerland	1.06	0.00	0.10	4.85	4.51	17.28	634.85
Germany	1.92	0.07	3.51	2.83	8.61	27.79	706.31

**Taking global cues, the Nifty is expected to open positive around 18700 and likely to remain range-bound in the price band of 18550-18750.**

The Nifty previous session ended 0.30% up at 18618.05. It opened on a flat note and moved up towards near all-time high around 18700 levels. Hence, staying cautious on rise is advised. Chart pattern suggesting range bound oscillation in the price band of 18550-18750 is likely. Index majors seen making a double top pattern, which is a concern. Immediate support is placed around 18550 levels.

On the Nifty hourly chart, direction of the leading indicators suggesting the benchmark index may remain stuck in the price band of 18550-18750. Staying cautious on rise is advised.

Nifty patterns on multiple periods suggesting; it ended in green. However, staying cautious on rise is advised. Broader chart pattern suggesting, the Nifty looks extremely overstretched and may see selling around 18700 levels.

The Bank Nifty previous session ended 0.08% up at 43053.45. It might get into the trading range of 42500-43700.

The Financial Nifty Fut trading range likely to be 18900-19300.

### **Nifty Crucial Supports & Resistances-**

**Supports- 18550, 18400 Resistances- 18700, 18740**

### **Open Positional Calls-**

T+15 INST POSITIONAL SELL-

| Fut Segment | TVS MOTOR @ 1100-1110, TGT- 1010, Closing SL- above 1160

T+15 INST POSITIONAL SELL-

| Fut Segment | ITC @ 350-355, TGT- 325, Closing SL- above 370

T+15 INST POSITIONAL SELL-

| Fut Segment | HDFC @ 2640-2660, TGT- 2520, Closing SL- above 2730

T+15 INST POSITIONAL BUY-

| Cash Segment | PAGE IND @ 46500-45500, TGT- 49500, Closing SL- below 44000

T+15 POSITIONAL SELL-

| Fut Segment | DLF @ 390-395, TGT- 365, Closing SL- above 410

T+15 INST POSITIONAL SELL-

| Fut Segment | SBIN @ 610-615, TGT- 575, Closing SL- above 635

T+15 INST POSITIONAL SELL-

| Fut Segment | CAN BANK @ 330-335, TGT- 295, Closing SL- above 355

T+5 BUY-

| Cash Segment | TECH MAHINDRA @ 1085-1080, TGT- 1130, Closing SL- below 1060

- **New Delhi Television:** Founders Prannoy Roy and Radhika Roy resigned from the board of the company's promoter group RRPR Holding.
- **Gland Pharma:** The company entered into a put option agreement to acquire 100% stake in France-based Phixen SAS, doing business under the brand name Cenexi, for 210 million euros (Rs 1,775.37 crore).
- **Biocon:** The company's subsidiary Biocon Biologics completed the acquisition of the biosimilars businesses and assets of Viatriis.
- **SBI/ HDFC Bank/ICICI Bank/Yes Bank/IDFC First Bank/Bank of Baroda/Union Bank of India/Kotak Mahindra Bank:** The Reserve Bank of India will start the pilot of for retail digital rupee on Dec. 01 through these eight banks.
- **IDFC:** SEBI has approved handing over control of IDFC Mutual Fund to a consortium led by Bandhan Financial Holdings.
- **Inox Wind/Inox Green Energy Services:** The companies have started the process of deleveraging their balance sheets, reducing a total debt of Rs 411 crore.
- **Krishna Institute of Medical Sciences:** The company raised its shareholding in subsidiary Arunodaya Hospitals to 65.62% by acquiring additional 7.79% stake.

### **Stocks Fluctuate in Asia Amid Focus on China, Fed**

Asian stocks seasawed as Chinese markets opened, with volatility in Hong Kong and mainland equities gauges as investors weighed Covid developments. US futures edged higher after stocks on Wall Street closed down and ahead of a speech from Federal Reserve Chair Jerome Powell later Wednesday. Treasuries were little changed while a dollar gauge declined. The offshore yuan fell after its biggest advance in more than two weeks on Tuesday. China purchasing managers index data contracted more than anticipated.

### **Oil Rises a Third Day on OPEC+ Cut Chatter, Falling Stockpiles**

Oil rose for a third day after industry data pointed to a substantial draw in US crude stockpiles and investors counted down to an OPEC+ meeting that may see the group agree to cut production. West Texas Intermediate climbed toward \$79 a barrel after adding 2.5% over the previous two sessions. The industry-funded American Petroleum Institute reported inventories fell by almost 8 million barrels last week, according to people familiar with the figures. Official data follow later on Wednesday.

### **Horizon Soars After Disclosing Talks with Amgen, Sanofi, J&J**

Horizon Therapeutics Plc soared in post-market US trading after the developer of medicines for rare autoimmune and inflammatory diseases said it's in talks with a trio of potential suitors about a possible sale of the company. Amgen Inc., Johnson & Johnson and Sanofi are separately engaged in preliminary discussions with Horizon, the company said in a statement on Tuesday. There's no certainty that any of the talks will lead to an offer. Dublin-based Horizon rose 30% in trading after markets closed in New York. Emerging from the exhausting focus on Covid-19, big drugmakers are resuming their search for innovative therapies, especially for those that treat rare diseases and cancer. Merck & Co. earlier this year scuttled an estimated \$37 billion bid for oncology drugmaker Seagen Inc., though it agreed this month to purchase Imago BioSciences Inc. to gain therapies for rare bone marrow conditions that lead to overproduction of blood cells. Horizon had dropped 27% this year through Tuesday's close, valuing the company at \$17.8 billion. The company gets almost half of its \$3.6 billion in annual sales from Tepezza, a treatment for a painful autoimmune condition called thyroid eye disease. Other top drugs include Krystexxa for chronic gout and Ravicti, a treatment for inborn urea disorders.

### Auto / Auto Ancillaries

[Toyota Kirloskar vice chairman Vikram Kirloskar no more](#)

[Passenger vehicle sales may have risen 33% in November](#)

[TVS Motor rolls out 2023 TVS Apache RTR 160 4V priced at Rs 1.30 lakh](#)

[Tata Motors, Mahindra & Mahindra are not giving up on diesel yet](#)

[Assam government's EV push: Indian Hotels starts EV charging station in Guwahati](#)

[Indonesia says lithium, anode plants are being built to support EV ambitions](#)

### Banking & Finance

[SBI cards tops HDFC Bank in incremental card issuances](#)

[Out-of-court deals gain traction as lenders, companies look to avoid IBC](#)

[The younger generation getting more credit conscious: Report](#)

[ARCs shift focus as retail NPAs rise: India Ratings](#)

[Gold loans: Banks are eating into NBFCs' market share](#)

### Oil & Gas

[ONGC gas price to be capped at \\$6.5 for 5 yrs, no change in Reliance-bp price](#)

[India panel to favour linking local gas prices to Indian crude basket: Sources](#)

[India to pitch for international biofuels alliance at G20: Hardeep Singh Puri](#)

### FMCG/Retail/Textiles/Agri

[On the cards: PLI-type scheme to replace textile tech fund](#)

[Liquor sales bubble over to 15% as demand increases for key segments](#)

[Big overseas brands sending out feelers for India debut](#)

[Britannia enters JV with Bel SA; to sell 49% stake in Britannia Diary](#)

[Amway repositions skin-care brand Artistry](#)

[Apple to lose 6 million iPhone Pros from tumult at China plant](#)

[Phone exports more than double year on year in April-October](#)

[Procurement from GeM crosses ₹1 L Cr in FY23](#)

[Black Friday outpaced Diwali and Dusherra sales for D2C brands - GoKwik](#)

### Metals/Mining/Power

[Central Electricity Authority projects 9 per cent jump in peak power demand to 235GW in April 2023](#)

[Inox GFL says wind businesses pay \\$50 million to reduce debt](#)

### IT/Telecom/Media

[NDTV says Prannoy, Radhika Roy resigned as directors of promoter group](#)

[DoT to telcos: No 5G sites near airports for now](#)

[TRAI seeks views on mandatory caller ID display on all mobile phones to check spam, fraud](#)

[CASHe partners with Jio Haptik to launch automated instant credit disbursements on WhatsApp](#)

[TRAI recommends separate permit for setting up satellite earth station gateways](#)

[ARPU for India's telcos likely to rise 8.2% in 2023: Fitch](#)

### Pharma/Fertilizers/Healthcare/Chemicals

[Manipal Health moves HC to halt Emami from selling its stake in AMRI Hospitals](#)

[Biocon raises \\$1.2 billion green loan to fund purchase of Viatris unit](#)

[Biocon completes \\$3.34 billion acquisition of Viatris's biosimilar business](#)

[Gland Pharma acquires French CDMO Cenexi for €120 million](#)

[Gland says not heard from its promoter Fosun about the potential sale](#)

[US drugmaker Amneal bets big on India formulation business](#)

[Tech-enabled healthcare innovations set to increase, says ZS PRIZE healthcare tech challenge jury member Aarti Shah](#)

### Hospitality/Aviation

[Vistara CEO Vinod Kannan tries to calm employees anxious over airline's merger with Air India](#)

[Vistara-AI merger: Tatas' another step to consolidate airline biz](#)

[Vistara: A long-cherished Tata-SIA dream that turned into reality in 2015](#)

[Vistara to merge with Air India, confirms Singapore Airlines](#)



### **Analyst Certification:**

We /I, Jaydeb dey Research Analyst(s) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

### **Terms & Conditions and Other Disclosures:**

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document



to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report or at the time of Public Appearance.

SMIFS does not have proprietary trades but may at a future date, opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/short position in the above Scrip(s) and therefore should be considered as interested.

The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing, however the same shall have no bearing whatsoever on the specific recommendations made by the analysts, as the recommendations made by the analysts are completely independent views of the Associates of SMIFS even though there might exist an inherent conflict of interest in some of the stocks mentioned in the Research Report.

The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at [www.nseindia.com](http://www.nseindia.com) and/or [www.bseindia.com](http://www.bseindia.com), [www.mcxindia.com](http://www.mcxindia.com) and/or [www.icex.com](http://www.icex.com).

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

### Specific Disclosures

- SMIFS, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- SMIFS, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company.
- SMIFS, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months.
- SMIFS, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as director/officer/employee in the subject company
- SMIFS has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- SMIFS has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- SMIFS has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months.
- SMIFS has not received any compensation or other benefits from third party in connection with the research report.
- SMIFS has not engaged in market making activity for the subject company

Analyst holding in stock: **NO**

---

### Key to SMIFS Investment Rankings

Buy: Return >15%, Accumulate: Return between 5% to 15%, Reduce: Return between -5% to +5%, Sell: Return < -5%

---

### Contact us:

**SMIFS Limited.** (<https://www.smifs.com/>)

### Compliance Officer:

**Sudipto Datta,**

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5401 /91 33 6634 5401

Email Id.: [compliance@smifs.com](mailto:compliance@smifs.com)

---